References
- Myasoedova E, Davis JM, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010;12:379–85.
- Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001;10:601–15.
- Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, . Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259–66.
- Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, . Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44:1984–92.
- McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. Br Med J 1999;319:312–15.
- Van Roon EN, Jansen TLTA, Mourad L, Houtman PM, Bruyn GAW, Griep EN, . Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol 2004;57:790–7.
- Wolfe F, Michaud K, Stephenson B, Doyle J. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate. J Rheumatol 2003;30:1725–32.
- Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45:S66–76.
- Siva C, Eisen SA, Shepherd R, Cunningham F, Fang MA, Finch W, . Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum 2003;49:745–51.
- Hajidiacos NP, Robinson DB, Peschken CA. Leflunomide in clinical practice: two-year population-based data with clinical validation. Arthritis Rheum 2002;46:S539.
- Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793–8.
- Wolfe F, Stephenson B, Doyle J. RA patients remain on leflunomide as long as methotrexate in clinical practice: accumulating evidence of long-term tolerability and effectiveness of leflunomide in RA. Arthritis Rheum 2001;44:S144.
- Jagoda JS, Rajapakse CNA. Leflunomide in clinical practice. A retrospective observational study on use of leflunomide in New Zealand. Int J Rheum Dis 2011;14:340–4.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
- Alivernini S, Mazzotta D, Zoli A, Ferraccioli G. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. Drugs Aging 2009;26:395–402.